text: <unk>  is a poly(ADP-ribose) polymerase (PARP) inhibitor that is FDA approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.   Common adverse reactions include thrombocytopenia, anemia, neutropenia, leukopenia, palpitations, nausea, constipation, vomiting, abdominal pain/distention, mucositis/stomatitis, diarrhea, dyspepsia, dry mouth, fatigue/asthenia, decreased appetite, urinary tract infection, AST/ALT elevation, myalgia, back pain, arthralgia, headache, dizziness, dysgeusia, insomnia, anxiety, nasopharyngitis, dyspnea, cough, rash, and hypertension.
option_0: Niraparib
option_1: Fomivirsen
option_2: Adefovir
option_3: Idraparinux
option_4: Vicriviroc
option_5: Remdesivir
option_6: Ribavirin
option_7: Letermovir